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Abstract
Background: Typhoid fever, caused by Salmonella enterica serovar Typhi (S. Typhi), is a major health problem especially in
developing countries. Vaccines against typhoid are commonly used by travelers but less so by residents of endemic areas.
Methodology: We used single nucleotide polymorphism (SNP) typing to investigate the population structure of 372 S. Typhi
isolated during a typhoid disease burden study and Vi vaccine trial in Kolkata, India. Approximately sixty thousand people
were enrolled for fever surveillance for 19 months prior to, and 24 months following, Vi vaccination of one third of the study
population (May 2003–December 2006, vaccinations given December 2004).
Principal Findings: A diverse S. Typhi population was detected, including 21 haplotypes. The most common were of the
H58 haplogroup (69%), which included all multidrug resistant isolates (defined as resistance to chloramphenicol, ampicillin
and co-trimoxazole). Quinolone resistance was particularly high among H58-G isolates (97% Nalidixic acid resistant, 30%
with reduced susceptibility to ciprofloxacin). Multiple typhoid fever episodes were detected in 22 households, however
household clustering was not associated with specific S. Typhi haplotypes.
Conclusions: Typhoid fever in Kolkata is caused by a diverse population of S. Typhi, however H58 haplotypes dominate and
are associated with multidrug and quinolone resistance. Vi vaccination did not obviously impact on the haplotype
population structure of the S. Typhi circulating during the study period.
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Introduction
Salmonella enterica serovar Typhi (S. Typhi) is the bacterium
responsible for typhoid fever, which affects more than 20
million people each year, resulting in over 200,000 deaths
[1,2]. As S. Typhi is transmitted by the fecal-oral route, the
typhoid fever burden falls almost exclusively in developing
areas where sanitation is poor [1,3]. The current mainstay of
typhoid fever treatment is antimicrobial therapy [4], however
resistance to antimicrobials is common among S. Typhi [5],
leading to prolonged bacterial clearance times and treatment
failure [6,7]. Children and young adults are the most
vulnerable population for developing typhoid fever [1,8,9]
and can be protected by vaccination against S. Typhi [10,11].
However while vaccines against S. Typhi are frequently used
by travelers to typhoid endemic areas [12], they are yet to be
effectively harnessed for the protection of local, typhoid
endemic populations [13].
S. Typhi is a highly clonal bacterium estimated to have entered
the human population on a single occasion approximately 50,000
years ago [14]. We have recently identified hundreds of single
nucleotide polymorphisms (SNPs) within the S. Typhi chromo-
some that are suitable for rapidly and informatively subtyping S.
Typhi populations [15,16]. As recombination is rare in S. Typhi,
SNP typing allows individual S. Typhi isolates to be assigned
unequivocally to unique haplotypes. Importantly, as haplotypes
are defined by phylogenetically informative sequence variation,
SNP typing also reveals information about genome sequence and
the evolutionary relationship between isolates [15,16]. As our SNP
panel is designed to allow inference of phylogenetic relationships,
it does not target SNPs that are likely to be under selection, such as
drug resistance loci. SNP haplotyping studies in localized areas
where typhoid is endemic, including Jakarta [17], Kathmandu
[18,19], the Mekong Delta [20] and Nairobi [21], have revealed
that the typhoid burden in endemic areas is usually attributable to
a diverse population of differentiable S. Typhi haplotypes, co-
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revealed the clonal expansion of a S. Typhi haplogroup, H58, in
South East Asia [16,18,20], as well as in Nairobi [21].
During 2003–2004, a typhoid burden study was conducted in a
typhoid endemic area of Kolkata, India [8,22,23]. This was
followed by a large-scale, cluster-randomized phase IV trial to
determine the efficacy of the injectable Vi polysaccharide vaccine
(Typherix, GlaxoSmithKline) among the local population
(.60,000 persons). The study site was divided into 80 geographic
clusters (40 clusters each randomly assigned to Vi vaccine or
inactivated hepatitis A vaccine as a control) and in December
2004, eligible residents were vaccinated (mean 60% of the
population vaccinated in each cluster) [11]. The primary results
of the trial, namely 61% efficacy among vaccinees and indirect
protection within and around Vi vaccinated geographic clusters,
have been published elsewhere [11,24]. Surveillance for fever was
conducted uninterrupted throughout May 2003–December 2006,
and typhoid fever was confirmed by positive blood culture of S.
Typhi [8,11,22,23]. A total of 372 typhoid cases were confirmed
by blood culture during the study period, including 197 during the
post-vaccination period. All S. Typhi isolates produced Vi during
in vitro culture [11], however Vi expression is tightly regulated in S.
Typhi growing on laboratory media and in vivo [25,26,27] and we
consequently hypothesised that selection against Vi expression in
Vi immunized individuals might result in differential efficacy of Vi
vaccine against different S. Typhi phylogenetic lineages. Here we
present an analysis of the 372 S. Typhi isolates collected during the
study period, including SNP haplotyping, antimicrobial suscepti-
bility profiling, analysis of intra-household transmission and
determination of Vi vaccine efficacy for the most common
circulating haplotypes.
Methods
Bacterial isolates
A total of 372 S. Typhi were isolated during the typhoid disease
burden study from May 2003 to December 2006, intervened by a
Vi effectiveness trial (December 2004), conducted in Kolkata,
India [8,11,22,23]. S. Typhi were isolated from blood cultures of
fever patients following standard techniques [28]. The institutional
review boards at the International Vaccine Institute, the National
Institute of Cholera and Enteric Diseases, and the Indian Council
of Medical Research approved the protocol and monitored the
progress of the studies. All subjects provided written informed
consent for vaccination and oral informed consent for blood
culture (for children, informed consent was provided by their
guardian). The assayed isolates represent all confirmed typhoid
cases during the study period May 2003 to December 2006,
among subjects who were present in the field area at baseline,
including 10 cases in non-vaccinees that were not included in the
original vaccine report due to incomplete demographic data [11].
Confirmation of S. Typhi was done by agglutination with poly and
monovalent antisera (BD diagnostics, US), Vi phenotype was
checked by agglutination with monovalent Vi antisera.
Antimicrobial susceptibility testing
Testing was performed using Kirby Baure’s disc diffusion
method using 11 antimicrobial discs from BD diagnostics
(ampicillin, tetracycline, chloramphenicol, cotrimoxazole, nalidixic
acid, ciprofloxacin, ofloxacin, ceftriaxone, amikacin, aztreonam,
amoxicillin-clavulanic acid). MICs of antimicrobials were deter-
mined by E-test (AB Biodisk, Solna, Sweden) and interpreted
following CLSI guidelines [29]. Multidrug resistance (MDR) was
defined as simultaneous resistance to chloramphenicol (MIC.
256 mg/mL), ampicillin (MIC.256 mg/mL) and co-trimoxazole
(MIC.32 mg/mL).
DNA extraction and SNP typing
DNA extraction was carried out from overnight LB culture of S.
Typhi isolates using Promega DNA extraction kit following
manufacturer’s instructions. DNA samples were quantified using
the Quant-IT kit (Qiagen, USA) and concentrations adjusted to
10 ng/ml using nuclease-free water (Ambicon, USA). SNP typing
was performed using either GoldenGate or Sequenom assays (loci
in Table S1). The former was performed using a GoldenGate
custom array according to the manufacturer’s standard protocols
(Illumina, USA), covering 1,500 loci (Table S1) as described
previously [18,20,21]. Briefly, DNA samples were arrayed in a 96-
well plate along with a negative control (water) and positive control
(sequenced Typhi), assayed using two custom oligo pools (200
SNPs included on both arrays for quality control) using the
Illumina GoldenGate platform and analyzed using Illuminus-P
[21]. Sequenom assays of 100 loci (Table S1) were performed
using the iPLEX Gold assay (Sequenom Inc, USA), designed using
the MassARRAY Assay Design software version 3.1 (Sequenom
Inc, USA) as previously described [19]. Samples were amplified in
multiplexed PCR reactions before allele specific extension. Allelic
discrimination was obtained by analysis with a MassARRAY
Analyzer Compact mass spectrometer. Genotypes were automat-
ically assigned and manually confirmed using MassArray Type-
rAnalyzer software version 4.0 (Sequenom Inc, USA).
Phylogenetic and statistical analysis
Phylogenetic analysis (Figure 1) was based on 81 SNPs common
to both GoldenGate and Sequenom assays (Table S1), which
include those dividing isolates into 48 major haplotypes (original
defined in [16]) and further subdivision of the H58 haplogroup
into subtypes (originally defined in [15]). Each isolate was assigned
to a node in the previously defined S. Typhi phylogenetic tree
based on alleles at these 81 SNP loci. Statistical analysis was
performed in R [30]. Haplotype-specific typhoid isolation rates in
Author Summary
Typhoid fever is caused by the bacterium Salmonella
enterica serovar Typhi (S. Typhi) and is a major health
problem especially in developing countries. Vaccines
against typhoid are commonly used by travelers but less
so by residents of endemic areas. We used single
nucleotide polymorphism (SNP) typing to investigate the
population structure of 372 S. Typhi bacteria isolated from
typhoid patients during a typhoid disease burden study
and Vi anti-typhoid vaccine trial in Kolkata, India.
Approximately sixty thousand people were enrolled for
fever surveillance for 19 months prior to, and 24 months
following, vaccination of one third of the study population
against typhoid (May 2003–December 2006, vaccinations
given December 2004). We detected a diverse population
of S. Typhi, including 21 different genetic forms (haplo-
types) of the bacteria. The most common (69%) were of a
haplogroup known as H58, which included all multidrug
resistant isolates (bacteria resistant to the antibiotics
chloramphenicol, ampicillin and co-trimoxazole). Resis-
tance to quinolones, a class of antibiotics commonly used
to treat typhoid fever, was particularly high among a
subgroup of H58 (H58-G). Vi vaccination did not obviously
impact on the haplotype distribution of the S. Typhi
circulating during the study period.
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www.plosntds.org 2 January 2012 | Volume 6 | Issue 1 | e1490Figure 1. S. Typhi haplotypes identified by SNP typing. Rooted phylogenetic tree indicating S. Typhi haplotypes defined by assayed SNPs,
scale as indicated. Haplotypes identified among 372 Kolkata isolates are labeled in black, the number of detected isolates for each haplotype is
indicated by bars according to the scale at the bottom. Bars are coloured to indicate major haplotypes, as in Figures 2, 3. The H58 haplogroup is
highlighted in grey, and is further divided into two major lineages I and II as indicated.
doi:10.1371/journal.pntd.0001490.g001
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using Fisher’s exact test (two-tailed test).
Results
Population structure of S. Typhi in Kolkata
All 372 S. Typhi isolates collected between May 2003 and
December 2006 were subjected to SNP haplotyping using high-
throughput Sequenom or Illumina GoldenGate platforms (Table
S1). These two genotyping methods have been applied previously
to study S. Typhi populations [17,18,19,20]. Forty-five of the
assayed loci were discovered by mutation analysis of 200 gene
fragments within a global collection of S. Typhi [16] and provide
medium-level resolution of the S. Typhi population, subdividing it
into 48 distinct haplotypes (displayed as a phylogenetic tree in
Figure 1). Eleven of these haplotypes, which are broadly
distributed across the tree, were identified among the Kolkata S.
Typhi (Figure 1, excluding shaded area). The globally dominant
haplotype H58 was by far the most common (N=260, 70%),
followed by H42 (N=65, 17%) and H14 (N=25, 7%) (Figure 1).
We assayed 50 additional SNP loci, discovered by whole genome
sequence analysis of seven globally distributed S. Typhi H58
isolates [15], that provide greater resolution within the H58
haplogroup and subdivide it into 20 distinct subtypes (Figure 1,
shaded area). Eleven H58 subtypes were identified among the
Kolkata S. Typhi (Figure 1), however 97% of H58 isolates
belonged to just four H58 subtypes: B (N=148, 40% of all S.
Typhi tested), G (N=66, 18%), A (N=22, 6%) and H64 (N=17,
5%).
S. Typhi haplotypes associated with antimicrobial
resistance
Resistance to the quinolone Nalidixic acid (Nal) was common
(54% of all isolates), with Nal resistance observed among
phylogenetically unlinked haplotypes (Table 2), indicating that
Nal resistance arises frequently within distinct S. Typhi chromo-
somal backgrounds. Each common haplotype included isolates
that were Nal resistant but susceptible to ciprofloxacin, as well as
isolates that were Nal resistant and exhibiting reduced suscepti-
bility to ciprofloxacin (MIC$0.125 mg/mL) (Table 2). Interest-
ingly the most common haplotype, H58-B, exhibited low rates of
Nal resistance, with only 24% of H58-B isolates displaying
resistance to Nal (significantly lower than other H58 (94%
resistant), p,10
28 using Fisher’s exact test). The highest rate of
Nal resistance was observed among the second-most common
haplotype, H58-G, with 97% of isolates resistant to Nal and 31%
also exhibiting reduced susceptibility to ciprofloxacin (Table 2).
Two isolates were ciprofloxacin resistant (MIC$16 mg/mL) and
have been described in detail elsewhere [31]. These isolates were
of identical haplotype, H58-I1 (see Figure 1) and isolated from
siblings (aged 3 and 5 years) on the same day in July 2004 [31]. No
other isolates of this haplotype were detected during the study
(2003–2006). Multiple drug resistance (MDR, defined as resistance
Table 1. Efficacy of Vi vaccine against major S. Typhi haplotype groups following vaccination.
Vaccinees Non-Vaccinees
Hep A
(typhoid cases)
Vi
(typhoid cases)
Rate
ratio
VE
[95% CI]
Hep A
(typhoid cases)
Vi
(typhoid cases)
Rate
ratio
VE
[95% CI]
H58 65 28 0.43 57% [33, 72]** 24 15 0.66 34% [226, 65]
H42 19 4 0.21 79% [38, 93]* 7 2 0.70 30% [245, 94]
Other 12 2 0.17 83% [26, 96]* 5 4 0.84 16% [2214, 77]
Total 96 34 0.35 65% [48, 76]** 36 21 0.62 38% [25, 64]
Persons 18,804 18,869 12,877 12,206
S. Typhi isolated during January 2005–December 2006 (i.e. within 24 months post-vaccination). Vi, geographical clusters randomly assigned to Vi vaccine against S.
Typhi; Hep A, control clusters assigned to hepatitis A vaccine; VE, vaccine efficacy;
*p,0.01;
**p,0.001 (Fisher’s exact test). There was no evidence for difference in efficacy between haplotypes (p.0.3, Fisher’s exact test).
doi:10.1371/journal.pntd.0001490.t001
Table 2. Distribution of quinolone resistance phenotypes
among S. Typhi haplotypes.
Haplotype Nal
R
Nal
S Total
Cip
S Cip
I Cip
R All
H58 subtypes
-A 14 3 0 17 5 22
-B 23 13 0 36 112 148
-E 2 100 1 01
-G 43 20 0 63 2 65
-G 0 100 1 01
- H64 12 5 0 17 0 17
- H65 100 1 01
-I 1 002 *2 02
-I 3 100 1 01
-I 4 100 1 01
-K 1 100 1 01
All H58 98 41 2* 141 119 260
H14 14 5 0 19 6 25
H16 100 1 45
H42 24 6 0 30 35 65
H50 400 4 26
H85 500 5 05
Other 100 1 56
Total 147 52 2* 201 171 372
Haplotypes are defined in Figure 1. Nal
S: Nalidixic acid susceptible (MIC,8 mg/
mL); Nal
R: Nalidixic acid resistant (MIC.256 mg/mL); Cip
S: ciprofloxacin
susceptible (MIC,0.125 mg/mL); Cip
I: ciprofloxacin reduced susceptible
(MIC$0.125 mg/mL); Cip
R: ciprofloxacin resistant (MIC.1 mg/mL);
*Cip MIC.16 mg/mL.
doi:10.1371/journal.pntd.0001490.t002
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in 43 S. Typhi isolates (11.5%), of which most (N=38) were also
Nal resistant. The MDR S. Typhi isolates belonged to five H58
subtypes: H58-A (5 isolates), H58-B (12 isolates), H58-G (10
isolates), H64 (a sub-type of H58) (15 isolates) and H58-I4 (1
isolate). These subtypes occupy the internal nodes of the H58
phylogeny, including members of both major lineages (see
Figure 1), indicating that MDR is widely distributed among the
H58 haplogroup.
Temporal patterns and the effect of vaccination on the S.
Typhi population
The incidence of typhoid fever remained high throughout the
four-year study period, with a median of seven cases per month
and no clear seasonal pattern (Figure 2). A total of 168 S. Typhi
were isolated during May 2003–November 2004 (19 month pre-
vaccination period), 7 during December 2004 (vaccination period)
and 197 during January 2005–December 2006 (24 month post-
vaccination period). The same haplotypes dominated throughout
the study (Figure 2), indicating that the burden of typhoid fever in
Kolkata was the result of a diverse range of co-circulating
haplotypes. One exception to this pattern was a peak in typhoid
cases in November 2005 involving 27 infections, of which 21 were
S. Typhi H58-B consistent with a small outbreak (Figure 2),
although no spatial clustering was evident. Only 2 of the 21 H58-B
cases in this month occurred in clusters assigned to Vi vaccine,
suggesting the vaccine was effective in providing protection during
the outbreak (Figure 2).
As previously reported, the incidence of typhoid fever during
the two years following vaccination was .60% lower among
individuals who received the Vi typhoid vaccine than those who
received hepatitis A vaccine (Table 1) [11]. Our haplotype data
indicates this overall reduction was due to a statistically significant
reduction in isolation rate across all S. Typhi haplotypes (H58,
H42 and others, see Table 1). All S. Typhi isolated during the
study, including those from individuals who had been vaccinated
with Vi (‘breakthrough cases’), reacted strongly with commercially
available Vi antisera (BD diagnostics, USA) in an agglutination
test, indicating that all strains could express the vaccine target Vi.
The 34 S. Typhi isolates from breakthrough cases belonged to
several distinct SNP haplotypes and were also diverse in terms of
antimicrobial resistance (Table 3).
Figure 2. Temporal distribution of S. Typhi haplotypes. Monthly frequency of S. Typhi coloured by haplotype (haplotypes defined in Figure 1).
Vaccines were administered in December 2004 (indicated by arrows) to approximately two thirds of the study population. (A) S. Typhi isolated from
typhoid fever patients in geographical clusters assigned to Vi vaccine. (B) S. Typhi isolated from typhoid fever patients in geographical clusters
assigned to hepatitis A vaccine.
doi:10.1371/journal.pntd.0001490.g002
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typhoid infections
There were 22 households from which multiple S. Typhi were
isolated by blood culture (21 households with 2 positive cultures; 1
household with 3 positive cultures, total 45 positive cultures;
Table 4). For three of these households, the paired isolates resulted
from two blood cultures from the same individual, taken 3–5
weeks apart and thus representing possible cases of relapse or re-
infection. Each of these isolate pairs displayed identical S. Typhi
haplotypes and resistance phenotypes, consistent with relapse as
opposed to re-infection with a distinct haplotype (Table 4).
However different S. Typhi haplotypes were involved in each pair
of these relapse cases, and displayed different antimicrobial
resistance profiles (H14, Nal
R; H58-G, MDR; H64, Nal
R+MDR).
In the remaining 19 households with multiple cases, S. Typhi
was isolated from different individuals, thus representing distinct
typhoid cases within the same household. Among these, twelve
households had more than one typhoid case occurring within two
months (Table 4). In nearly all of these households, the same S.
Typhi haplotype (displaying same resistance phenotype) was
isolated from both cases, consistent with direct transmission
between household members or a shared environmental source
such as food or water (10/12 households, Table 4, p=0.039 using
Binomial test with equal probability of same or different
haplotypes). Among households in which a second typhoid case
occurred more than two months after the first, the later infection
was most often caused by a distinct S. Typhi haplotype (5/7
households, Table 4). To examine whether Vi vaccination reduced
intra-household transmission, we compared the proportion of
Figure 3. Spatial distribution of S. Typhi haplotypes. Maps of the study site, illustrating the division of the site into 80 geographical clusters
randomly assigned to receive Vi or control (hepatitis A) vaccine. The location of each typhoid fever patient’s residence is indicated by a star, coloured
by the haplogroup of the corresponding S. Typhi isolate. (A) S. Typhi isolated before administration of vaccine (May 2003–November 2004). (B) S.
Typhi isolated after administration of vaccine (January 2005–December 2006).
doi:10.1371/journal.pntd.0001490.g003
Table 3. Haplotypes and antimicrobial sensitivity phenotypes
for S. Typhi isolated from individuals vaccinated with Vi.
Haplotype Resistance phenotype No. isolates
H14 Nal
R 1
H37 S 1
H42 S 1
H42 Nal
R 3
H58-A Nal
R 1
H58-B S 11
H58-B Nal
R 3
H58-G MDR 1
H58-G Nal
R 7
H58-G Nal
R, MDR 3
H58-H64 Nal
R 1
H58-H64 Nal
R, MDR 1
Haplotypes correspond to those defined in Figure 1. Nal
R: Nalidixic acid
resistant (MIC.256 mg/mL); MDR: multidrug resistant, defined as resistant to
chloramphenicol (MIC.256 mg/mL), ampicillin (MIC.256 mg/mL) and co-
trimoxazole (MIC.32 mg/mL); S: susceptible to all antimicrobials tested.
doi:10.1371/journal.pntd.0001490.t003
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household (defined as the same S. Typhi haplotype isolated from
another member of the household one week to two months after
the initial case), among Hepatitis A and Vi clusters in the post-
vaccination period. While it is possible that two typhoid cases
caused by the same haplotype in the same household could result
from shared exposure to a common source of S. Typhi, it is more
likely that infections separated by more than a week constitute
transmission events. Using this definition of household transmis-
sion, six percent (8/135) of cases in the Hepatitis A cluster were
linked to putative transmission within a household, while none of
the 59 cases in the Vi cluster were obviously linked to transmission.
While the numbers are low, this provides weak evidence for
protection against person-to-person or direct transmission by the
Vi vaccine (p=0.045 using Fisher’s exact test), which may be via
direct protection of vaccinated individuals and/or indirect
protection via herd immunity in clusters assigned to the Vi
vaccine. The distribution of haplotypes among these likely
transmission events was no different to that of haplotypes among
all Hepatitis A clusters during the post-vaccination period (5 cases,
8% for H58-B; 1 case, 6% for H580-G; 1 case, 4% for H42; p=1
using Fisher’s exact test). Thus there is no evidence that any
particular haplotype is more likely to be transmitted person-to-
person.
Discussion
S. Typhi populations in Kolkata and other typhoid
endemic areas
SNP typing of S. Typhi isolated during 2003–2006 revealed a
diverse range of haplotypes co-circulating in the study site, an
urban slum area in eastern Kolkata. A similar level of diversity has
been observed in previous studies in typhoid endemic areas
[17,18,20,21]. The dominant S. Typhi haplotypes were subtypes
of H58, collectively accounting for 70% of all S. Typhi isolated
during the four-year study (Figure 1). The dominance of H58 has
been reported in recent studies of S. Typhi infections in other
typhoid endemic areas including Kathmandu, Nepal (69% H58,
2003–2004) [18], the Mekong Delta, Vietnam (98% H58, 2004–
2005) [20] and Nairobi, Kenya (87% H58, 2001–2008) [21].
However there does appear to be greater diversity within the H58
group in Kolkata. We identified 11 distinct H58 haplotypes,
including four with high frequency among S. Typhi from Kolkata
(18–150 isolates each) including the ancestral node (A) and nodes
from both major lineages of H58 (Figure 1). In neighbouring
Nepal, two hospital-based studies of S. Typhi found 61–69% of
isolates belonged to a single subtype of H58 lineage II, H58-G,
and few other H58 isolates were detected [18,19]. In the Mekong
Delta, Vietnam, a large hospital-based study found 95% of S.
Table 4. Details of households with multiple confirmed typhoid fever cases.
Case 1 Case 2 Time to 2
nd case Different haplotype Relapse/reinfection
House Cluster Hap Vi vacc Hap Vi vacc
A Hep A H14 - H14 - 17 days - yes
B Hep A H64 - H64 - 23 days - yes
C Vi H58-G yes H58-G yes 34 days - yes
D Hep A H58-G - H58-G - 0 days - -
E Vi H42 - H42 - 8 days - -
F Hep A H42 - H42 - 8 days - -
G Hep A H14 - H14 - 8 days - -
H Hep A H58-B - H58-B - 10 days - -
I Hep A H58-B - H58-B - 22 days - -
J Hep A H58-G - H58-G - 28 days - -
K Hep A H58-B - H58-B - 34 days - -
L Hep A H58-B - H58-B - 2 mo - -
M Hep A H58-B - H58-B - 2 mo - -
N Hep A H58-B - H58-B - .10 mo - -
O Hep A H58-B - H58-B - .1y r - -
P Vi H85 - H64 - 33 days yes -
Q Hep A H58-B - H58-G - 2 mo yes -
R Hep A H58-G - H14 - .3 mo yes -
S Hep A H58-B - H58-G - .4 mo yes -
T Hep A H58-B - H58-A - .4 mo yes -
U Hep A H55 - H58-G - .1 yr yes -
M* Hep A H58-B - H42 - 1 yr yes -
V Vi H42 - H58-B yes .2 yr yes -
House=household identifier; Cluster=geographic cluster for vaccine trial; Hap=S. Typhi haplotype; Vi vacc=received Vi vaccination prior to typhoid fever episode;
Case 1, Case 2=first and second case occurring in household; Time to 2nd case=time between S. Typhi-positive blood culture collection from cases 1 and 2; Different
haplotype=case 2 haplotype differs from first case; Relapse/reinfection=case 2 occurred in same individual as case 1;
*three cases detected in household, row indicates comparison of case 1 to case 3.
doi:10.1371/journal.pntd.0001490.t004
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belonged to one of three closely related H58 lineage I subtypes,
H58-C, -E1 and -E2 (see Figure 1) [20]. In that study,
differentiation of the three subtypes was possible because the
genome of an isolate from the study had been sequenced for the
purpose of SNP discovery [15].
Diversification and differentiation within S. Typhi H58
The H58 subtypes that were common in the present study in
Kolkata are internal nodes of the H58 phylogenetic tree described
by the assayed SNPs (A, B, G, H64, see Figure 1). This is not
particularly surprising, since SNP discovery for our assays did not
include analysis of any Kolkata strains, with the exception of two
isolates of the H64 haplotype (actually part of the H58 group, see
Figure 1) which were included in mutation detection within 200
gene fragments [16] but not at a genome-wide scale [15]. Since
SNPs accumulate locally over time as bacteria replicate, we would
expect that there is more diversity in the Kolkata S. Typhi
population than we are able to detect in our SNP assays (i.e.
mutations have occurred locally at genomic positions that we did
not assay). If more Kolkata isolates had been included in SNP
discovery, we would be able to differentiate among Kolkata
isolates at higher resolution. This is known as SNP ascertainment
bias [32], and implies that diversity which has accumulated in the
local S. Typhi H58 population of Kolkata in the last decade or so is
being collapsed into just a few haplotypes using our SNP typing
method. Despite this, the fact that both major H58 lineages and
the ancestral node were detected at high frequency in Kolkata
indicates that H58 S. Typhi has been present in this location for
some decades. This is similar to the pattern observed in Kenya
where both H58 lineages have been observed at high frequency
[21], but quite unlike Vietnam or Nepal where lineage I or II
dominated, respectively.
Antimicrobial resistance
In this study, as in others, antimicrobial resistance was frequent
among H58 S. Typhi. All MDR isolates were from the H58 group,
similar to recent observations in Vietnam [20], Kenya [21] and
global collections [33]. Nal resistance was frequent among all H58
subtypes except H58-B (25% of H58-B; 95% of all other H58, see
Table 2), although it was also frequent among common non-H58
haplotypes H42 (46%) and H14 (76%). Interestingly, S. Typhi
H42 was also common in the Nepal study (19% of S. Typhi), yet
Nal resistance in that location was observed only among H58-G
isolates. Taken together, these observations suggest that while
MDR is now largely restricted to H58 S. Typhi, Nal resistance
arises frequently in S. Typhi of a diverse range of haplotypes.
Household clustering of typhoid
Several households experienced more than one typhoid
infection during the study. Among multiple cases occurring in
the same household within a 2-month period, nearly all (10/12)
were caused by identical infecting S. Typhi haplotypes, consistent
with intra-household transmission or a common source (Table 4).
In the post-vaccination period, eight such putative transmission
events were detected in control clusters (assigned to Hepatitis A
vaccine) and none were observed in Vi vaccine clusters, possibly
reflecting protection via vaccination and/or herd immunity in
these clusters. Three cases of relapse were identified (two infections
with the same haplotype in a single individual). Although each pair
of relapse isolates had an identical haplotype the haplotype was
different in each individual, although all exhibited some form of
antimicrobial resistance (Nal
R and/or MDR), suggesting that
relapse may be associated with antimicrobial failure.
Impact of the Vi vaccine
In addition to providing a snapshot of the S. Typhi population
circulating in a localized region of Kolkata, this study offers the
first insight into the impact of the introduction of Vi typhoid
vaccine upon a local S. Typhi population. Our data indicate the
incidence of all haplotypes of S. Typhi was similarly reduced
among Vi vaccinated individuals (Table 1, Figure 2). S. Typhi
isolated from Vi vaccinated individuals included several distinct
haplotypes, which could be further differentiated by antimicrobial
resistance phenotypes (Table 3). All S. Typhi isolates expressed Vi
during laboratory culture. Thus, it is likely that ‘breakthrough’
cases of typhoid fever among vaccinees is due to subtle variations
in the regulation of Vi expression in vivo and/or to host factors, and
not to lineage-associated differences in Vi expression.
Conclusions
The S. Typhi population responsible for typhoid fever in
Kolkata is genetically and phenotypically diverse, displaying a
wide range of haplotypes and antimicrobial susceptibility pheno-
types. However the H58 haplotype dominates, and is responsible
for the majority of MDR and quinolone resistant S. Typhi
infections. The Vi polysaccharide vaccine was effective against
infections with all S. Typhi haplotypes.
Supporting Information
Table S1 S. Typhi SNP loci assayed in this study. SNPs
are identified by their coordinate within the S. Typhi CT18
reference genome (NC_003198).
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